Injectables
Revance Nears Launch for Botox Rival While AbbVie Sues in Response
InjectablesRevance Nears Launch for Botox Rival While AbbVie Sues in ResponseRevance Nears Launch for Botox Rival While AbbVie Sues in Response
Revance Therapeutics has travelled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, it faces a new obstacle: a patent lawsuit from drug giant AbbVie.
Subscribe to receive the latest in aesthetic medicine.
Get breaking developments, expert product comparisons, clinical roundtables, and practice strategies—all for free.